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Background: Currently, the two most commonly used fibrinolytic agents in thrombolytic therapy are recombinant
tissue plasminogen activator (rt-PA) and streptokinase (SK). Whereas SK has the advantage of substantially lower
costs when compared to other agents, it is less effective than either rt-PA or related variants, has significant
allergenic potential, lacks fibrin selectivity and causes transient hypotensive effects in high dosing schedules.
Therefore, development of an alternative fibrinolytic agent having superior efficacy to SK, approaching that of rt-PA,
together with a similar or enhanced safety profile and advantageous cost-benefit ratio, would be of substantial
importance. Pre-clinical data suggest that the novel fibrinolytic recombinant staphylokinase (rSAK), or related rSAK
variants, could be candidates for such development. However, since an efficient expression system for rSAK is still
lacking, it has not yet been fully developed or evaluated for clinical purposes. This study’s goal was development of
an efficient fermentation process for the production of a modified, non-glycosylated, biologically active rSAK,
namely rSAK-2, using the well-established single cell yeast Hansenula polymorpha expression system.
Results: The development of an efficient large scale (80 L) Hansenula polymorpha fermentation process of short
duration for rSAK-2 production is described. It evolved from an initial 1mL HTP methodology by successive scale-up
over almost 5 orders of magnitude and improvement steps, including the optimization of critical process parameters
(e.g. temperature, pH, feeding strategy, medium composition, etc.). Potential glycosylation of rSAK-2 was successfully
suppressed through amino acid substitution within its only N-acetyl glycosylation motif. Expression at high yields
(≥ 1g rSAK-2/L cell culture broth) of biologically active rSAK-2 of expected molecular weight was achieved.
Conclusion: The optimized production process described for rSAK-2 in Hansenula polymorpha provides an
excellent, economically superior, manufacturing platform for a promising therapeutic fibrinolytic agent.
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Staphylokinase (SAK), a protein produced by certain
Staphylococcus aureus (S. aureus) strains, was found to
possess pro-fibrinolytic properties almost 6 decades
ago [1-3]. In comparison with streptokinase (SK), re-
combinant wild-type staphylokinase (wt-SAK) has shown
higher fibrinolytic efficacy as well as lower fibrinogen-
olytic effects [4]. However, as a heterologous (bacterial)
protein, wt-SAK produces immunogenic effects in ani-
mals that compromise its effectiveness on repeated* Correspondence: mueller@minapharm.com
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reproduction in any medium, provided the oradministration and thus, potentially, its efficacy in clin-
ical applications [5].
Laroche et al. [6] showed that wt-SAK immunogenicity
can be significantly reduced by site-directed mutagenesis
to eliminate antigenic epitopes present within the pro-
tein sequence, while conserving its activity. Since then,
several studies have investigated the immunogenic and
activity properties of numerous SAK variants. In pre-
clinical trials, a sequence optimized SAK variant named
THR174, developed at ThromboGenics NV [www.
thrombogenics.com; [7], showed improved efficacy and
safety profiles as well as significantly reduced immuno-
genicity compared with SK and other SAK variants.l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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SAK variants are routinely produced in Escherichia coli
(E. coli) [8] and Bacillus subtilis (B. subtilis) [9] expres-
sion systems. The methylotrophic yeast Hansenula poly-
morpha (H. polymorpha) provides an alternative
expression system and has already been successfully
developed for several commercial production processes,
e.g. HBsAg vaccine particles, Interferon-α2a and Hirudin
[10-12]. H. polymorpha is able to utilize methanol as
sole carbon source, resulting in over-expression of
‘methanol utilization’ enzymes, namely methanol oxidase
(MOX), dihydroxyacetone synthase (DHAS) and formate
dehydrogenase (FMD). Heterologous DNA is readily and
stably integrated into the H. polymorpha genome using
routinely applied techniques to achieve high copy, heter-
ologous gene numbers. The strongly inducible promo-
ters of the MOX and FMD genes are commonly used as
regulatory components for enhanced heterologous gene
expression, by which correspondingly high protein con-
centrations, up to 70% of total soluble cell protein con-
tent, are attained [11]. Furthermore, the S. cerevisiae-
derived MFα1 leader sequence can be used to target the
heterologous protein produced in H. polymorpha for se-
cretion, allowing its easy recovery from the fermentation
broth [13-17].
The combination of stable heterologous gene expres-
sion, synthesis and secretion of high concentrations of
recombinant proteins, the advantageous characteristics
of the H. polymorpha expression system, would appear
to provide the means for developing a production
process for a potentially clinically superior rSAK variant.
Therefore, the aim of this study was the development of
an efficient H. polymorpha fermentation process in
stirred tank bioreactors to yield high concentrations of
the rSAK variant, THR174 [7]. The full upstream devel-
opment, starting with gene design, cloning and media
optimization at the micro-scale, up to large scale fer-
mentations in stirred tank bioreactors is described.
Results and discussion
Strain selection
Initial trials for the correct protein expression productiv-













Figure 1 Amino acid sequences of wt-SAK and SAK-variants [rSAK-1 (
different SAK molecules, highlighting the differences in their primary struct
Red underlined: Amino acid exchange Thr-30→ Ala-30.(strains) were performed in shake flasks using YPG
medium. As shown in Western blots of culture super-
natants from the rSAK-2 strain (Figure 2a), a single
well-defined band at around 16 kDa that migrated paral-
lel to that of E. coli-produced rSAK-1 (ThromboGenics
NV) is present. The rSAK-1 strain, however, produced
an additional ‘smear-like’ band between 20 kDa and
25 kDa, indicating glycosylated rSAK-1.
Endoglycosidase H treatment of supernatant from the
rSAK-1 strain’s fermentation led to removal of the
smear-like band, while the well-defined band at 16 kDa,
corresponding to correctly processed, non-glycosylated
rSAK-1, significantly increased in intensity (Figure 2b).
This provided evidence that the (H. polymorpha) rSAK-1
strain secretes both glycosylated and non-glycosylated
rSAK-1, while the rSAK-2 strain secretes only non-
glycosylated rSAK-2 (Figure 2b).
Since glycosylated rSAK-1 is known to have substan-
tially reduced enzymatic activity and was predicted to
pose various difficulties for downstream processing and
product characterization [13,17], the rSAK-2 strain se-
creting only non-glycosylated rSAK-2 was chosen for
further process development.
A series of different cultivation techniques were ap-
plied during the upstream development. Cultures ranging
from 1 mL volume to 80 L volume scale were investi-
gated under fully and/or partially controlled conditions.
An overview of applied cultivation systems and their
usage in this study is provided in Table 1.
Fermentation process development and scale-up
The upstream process development was started in the
microscale BioLectorW and small scale shake flask sys-
tems. The process was further developed in 300 mL and
2 L scale bioreactors and finalized with a linear scale-up
to 8 L and 80 L.
Microscale BioLectorW
pH optimization
Optimization of rSAK-2 expression was commenced at
the micro-scale fermentation level (1 mL) by studying
biomass growth and protein expression ratio in SYN6






= THR 174) and rSAK-2]. The amino acid sequence of each of the
ures (blue), is shown. Red: Potential N-linked glycosylation-site motif.
Figure 2 a. Western blot analysis of supernatants from rSAK producing strains. Lane 1 THR 174 ~ 60ng; RB11/pFPMT Mfα+ - rSAK-1
(lane 2 – 10) and RB11/pFPMT Mfα+ - rSAK-2 (lane 11–18); 7 μL loaded. b: Glycosylation evidence for SAK: SDS-PAGE analysis of de-repression
supernatants. (Pool 1) was de-repressed in YP 2% glycerol for 40 h at 30°C and 37°C. Pooled supernatants of pool 1 were treated with EndoH
(lane 4 and 6). Supernatants without EndoH treatment (lane 3 and 5) have been handled with the same EndoH buffers but omitting EndoH. After
EndoH treatment, samples were prepared for SDS PAGE and 21 μL each was loaded on a Criterion 4-20% precast gradient gel. Supernatants have
been finally examined in a Western blot analysis for presence of SAK. SAK protein was detected by using alkaline phosphatase-conjugated mouse
anti-SAK antibody. Approximately 180 ng of THR174 served as positive control.
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was only detected between pH 6 and 7. At pH values
higher than 7, biomass growth was significantly inhibited
(data not shown). In addition, published data on pH sta-
bility of SAK [18] indicated that it is most stable be-
tween pH 6 and 7. Therefore, a constant pH of 6.5 was
chosen for all following micro-scale experiments.
Medium optimization
The effect of addition of 20 different plant peptones
to SYN6 medium on rSAK-2 expression was assessed(Figure 3). From this survey, 7 promising peptone candi-
dates were picked for further kinetic investigations. For
this purpose, 3 different phases of sampling of the fermen-
tation process were indicated by the online process data:
1. sampling - end of exponential phase; 2. sampling -
2 hours after entry into stationary phase and 3. sampling -
5 hours after entry into stationary phase (Figure 4).
In general, the secreted protein in the cell super-
natant is stabilized by peptones, though not all pep-
tones have a positive effect on protein expression. We
found fermentations with wheat peptone yielded highest,
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Figure 3 Western blot analysis of rSAK-2, expressed in SYN6 medium supplemented with 20 different plant peptones and a
comparative fermentation without peptone. Results from a 1 ml micro scale batch fermentation in the BioLectorW system (5 μL supernatant
loaded). Final lanes loaded with THR-174 (~109 ng). The most prominent SAK-2 signals appeared for vegetable peptone (1) and wheat
peptone (17).
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Figure 4 Western Blot analysis of rSAK-2, expressed in SYN6 medium supplemented with different plant peptones and a comparative
fermentation without peptone (5 μL supernatant loaded). Sampled: a) at the end of exponential phase, b) after 2 hours and c) after 5 hours
after the entry in stationary phase. Highest results from a 1 mL micro scale batch fermentation in the BioLectorW system were attained with
wheat peptone (17) followed by vegetable peptone (1). Final lanes were loaded with THR-174 (~109 ng).
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peptones, or just ‘no peptone supplementation (w/o)’,
resulted in degradation of rSAK-2 over time (data not
shown). Consequently, wheat peptone was chosen for
all further experiments.
Feed strategy
In further micro-scale experiments using SYN6 medium
supplemented with 10 g/L wheat peptone, two feedFigure 5 Biomass growth over time of a glycerol fed-batch culture an
media. The Fed-Batch culture was pulsed twice at t = 1 and 2 with a mixt
points of time (1–4) a sample was taken. For the other culture, methanol w
taken at t = 1 and 3. Fermentation was carried out at 1mL scale in the BioL
expression (5 μL supernatant loaded). Standards (std) are drawn for the indstrategies were assessed in parallel. In the first, a ‘pulsed’
glycerol-peptone fed-batch fermentation was carried out.
The feed solution was pulsed manually at the end of the
exponential growth phase when the dissolved oxygen
(DO) signal increased. This was done twice during fer-
mentation at the time points indicated (Figure 5). At
time points 1 to 4, samples were taken. In the second, a
culture was induced with methanol at time point 1. The
methanol-induced culture received no additional nutrientsd a methanol induced culture, respectively, grown in SYN6
ure of 10 g/L glycerol and 10 g/L peptone (final concentration). At four
as given once (1) at a final concentration of 10 g/L. Samples were
ectorW system. Samples were analysed in a Western Blot for rSAK-2
ividual gels. Final lanes were loaded with THR-174 (~109 ng).
Table 2 Overview of SYN 6.[X] media compositions
Media Components SYN 6 SYN 6.4 SYN 6.46d
Glycerol 2% w/v 2% w/v 2% w/v
Salt mix solution 10% v/v 5% v/v 5% v/v
Wheat peptone - 4% w/v 4% w/v
Yeast extract - 3% w/v 3% w/v
CaCl2 solution 1% v/v 2% v/v 2% v/v
Vitamins solution 1% v/v 0.5 % v/v -
Micro elements solution 1% v/v 0.5 % v/v 0.5 % v/v
Trace elements Solution 1% v/v 0.5 % v/v -
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points 1 and 3.
RP-HPLC analysis of samples from the two feeding
strategies revealed a 1.5-fold higher rSAK-2 protein
concentration for the methanol-induced culture versus
the ‘pulsed’ glycerol-peptone fed-batch (90 mg/L versus
60 mg/L, respectively). Therefore, it was decided to
base further fermentation strategy experiments on the
methanol induction procedure.
Small scale shake flasks
Temperature
Shake flask batch fermentations comparing temperatures
of 30°C and 37°C were performed. The cells consistently
showed higher growth at 30°C compared to 37°C. The
maximum OD600 reached at 30°C was around 40,
whereas at 37°C it was around 30. While this slightly
higher cell growth rate at 30°C was not significant, a fer-
mentation temperature of 30°C was set for all following
investigations.
Media optimization
In small scale shake flask fermentations performed in
parallel with micro-scale experiments, the effect on
rSAK-2 concentration of adding yeast extract to SYN6
medium was assessed. This was carried out together
with varying combinations and concentrations of the
medium’s components, including wheat peptone.
Twenty seven different variations of medium supple-
ments were tested in batch fermentations without feed
addition. The supplemented medium yielding the high-
est rSAK-2 concentration, 31 mg/L as determined by
RP-HPLC, was selected for further optimization. The
‘in-house developed’ medium named SYN6.4 contained
4% w/v wheat peptone and 3% w/v yeast extract and had
modified concentrations of 1% v/v each of the four sup-
plement solutions (normally 2% v/v CaCl2, 0.5% v/v vita-
mins, 0.5% v/v micro elements and 0.5% v/v trace
elements), which are components of ‘classical’ SYN6
medium.
Further optimization of SYN6.4 medium was per-
formed in fed-batch fermentations at the shake flask
scale. Our approach was to remove one or more of the
defined components of SYN6.4 medium in each flask in
order to discover “inessential” constituents and those
that are limiting for rSAK-2 expression. Interestingly, it
was found that the highest rSAK-2 yield of 200 mg/L oc-
curred when all defined trace elements and vitamins to-
gether with EDTA were removed from the medium. We
called this medium SYN6.46d (Table 2).
Feed strategy optimization
The feed strategy of methanol induction developed in
the microscale BioLectorW was tested and furtheroptimized in fed-batch shake flasks. In addition to
methanol, glycerol was added to the feed solution (FS)
to maintain cell growth during the initial period of the
fed-batch phase. We also added wheat peptone and yeast
extract to the FS to replenish the nutrients consumed
during growth. The feed strategy with these 4 supple-
ments led to a significant increase in expressed r-SAK-2
(Table 1). Different amounts of the feed solution supple-
ments were then tested in the 300 mL bioreactor.
300 mL scale bioreactor
pH optimization Stirred bioreactor fermentations per-
mitted implementation of a wider pH range. Due to
the ability to control the pH, it was decided to keep it
constant during the biomass growth phase at 5.5 to
maintain a reasonable growth rate. Then, without signifi-
cantly limiting biomass growth, to increase the pH grad-
ually during the fed-batch phase to 6.3 to promote
increased rSAK-2 expression, secretion and stability.
Feed strategy optimization Using the in-house devel-
oped medium SYN6.46d for fermentation, we performed
fed-batch cultivations in 300 mL DASGIP bioreactors in
order to ascertain the optimum composition of the ‘feed-
ing solution’ (FS).
Two different FS were compared. The first FS consisted
of 20% yeast extract (w/v), 10% peptone (w/v), 5% gly-
cerol (w/v) and 10% methanol (w/v) (called FEED_I).
The second FS had increased peptone and glycerol con-
centrations and consisted of 20% peptone (w/v), 10%
glycerol (w/v), 20% yeast extract (w/v) and 10% metha-
nol (w/v) (called FEED_II). Feeding was done in lots of
20 mL FS every 5 hours and was automated via the
DASGIP bioreactor’s pump module. RP-HPLC analysis
of culture supernatants gave concentrations of 149 and
213 mg rSAK-2/L for FEED_I and FEED_II, respectively.
Their specific productivities were 0.018 and 0.027 mg/
OD600/h respectively. Therefore, FEED_II was chosen
for all subsequent experiments.
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known that different feeding strategies can significantly
impact on heterologous protein production. In the 300
mL DASGIP bioreactor, we compared the ‘batch-wise
mode’ feeding with a 20 mL FS [FEED_II] every 5 hours
against a ‘constant feeding mode’ with a rate of 4 mL FS/
hour, as well as a pO2-driven feeding procedure. The
constant feeding mode of 4 mL FS/hour gave the highest
rSAK-2 expression at 423 mg/L, significantly more than
the other two feeding strategies; 304 mg/L with batch-
wise feed and 295 mg/L with pO2-driven feed.
Scale-up and optimizations in 2 L bioreactors
While attaining rSAK-2 concentrations of around
400 mg/L at the 300 mL fermentation scale over
48 hours’ duration, it was necessary to reproduce this
yield in a scaled-up fermentation of 2 L. For scale-up
trials, the conditions that were found best during our
previous experiments at the 300 mL scale were used.
These included the use of the in-house developed












Figure 6 Typical RP-HPLC profile of a final rSAK-2 fermentation superoptimal FS composition. However, aeration, pH and
stirring had to be adjusted as described in the methods
section. The feeding rate was set to 18 mL/hour to
match the larger cultivation volume.
Under such optimized conditions, trials at the 2 L
scale resulted in rSAK-2 yields of up to 480 mg/L.
As sampling at different fermentation times has shown
increasing rSAK-2 expression, fermentation to a total of
70–73 hours with constant feeding over 50 hours was
evaluated. Due to the requirement for increased volume
of feed solution, the initial volume of medium had to be
reduced from 1.4 to 1.2 L, the feed rate re-adjusted to
20 mL/hour and the FS composition re-adjusted to 20%
peptone (w/v), 22% glycerol (w/v), 20% yeast extract
(w/v) and 15% methanol (w/v). An rSAK-2 concen-
tration of 1212 mg/L was attained under these final
optimized conditions. This production level was repro-
ducible and consistent in several fermentations (data
not shown). Figure 6 shows a typical RP-HPLC profile
for an rSAK-2 containing supernatant at the end of





natant sample at 73.5 hours of cultivation.
Table 3 rSAK-2 concentrations attained at the 8L and 80L
scale
Trial Scale rSAK-2 concentration [mg/L]
1 8 L 1081
2 8 L 925
3 80 L 1109
Moussa et al. BMC Biotechnology 2012, 12:96 Page 8 of 13
http://www.biomedcentral.com/1472-6750/12/96Scale-up to 8 L and 80 L bioreactors
The final optimized conditions for the 2 L scale were
successfully transferred to the 8L and 80L scales (see
Figures 7a and b). To show the reproducibility of the fer-
mentation process at these volumes, two trial fermenta-
tions were performed at the 8 L scale and one at the 80L
scale, with the following results: (Table 3).
Activity measurement by the plasminogen activation
assay (PAA) for fermentation supernatant samples gave
a specific activity of rSAK-2 within the range of that of
the recombinant SAK (STAR) reference standard 94/718
(obtained from The National Institute for Biological
Standards and Controls (NIBSC), UK). Specific activity






































Figure 7 a. Overlay of OD600 values for rSAK-2 fermentations at differ
fermentations at different bioreactor scales.that the STAR reference standard is a purified lyophi-
lized material stabilized in an albumin containing phos-
phate buffer.
That cell growth, as measured OD600 values, at the 8 L
and 80 L bioreactor scale was higher than at the 2 L




ent bioreactor scales. b: Overlay of rSAK-2 titers for
Table 4 Summary of specific biological activities for rSAK-2 from crude fermentation supernantant samples after
harvest compared to the SAK reference standard from NIBSC
Scale/Sample Measurement number Concentration by PAA [μg/ml] Activity by PAA [IU/ml] Specific activity [IU/mg]
80 L scale Batch 1 1 883.87 55.59 58.302
2 783.87
Batch 2 1 649.03 42.32 58.376
2 620.65
Batch 3 1 816.13 52.42 56.232
2 756.45
2 Lscale 1 999.19 60.73 58.446
2 822.58
SAK STAR NIBSC 94/718 (1 IU =
15 μg as described in datasheet)
Theoretical value 15 1 66.667
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rSAK-2 concentrations attained in the 2 L, 8 L and 80 L
bioreactors were within the same range. Taking into ac-
count the differences in cell growth, the specific prod-
uctivity at larger scales was lower than in the 2 L
bioreactor (Table 1).
Development and optimization of the H. polymorpha
fermentation process for rSAK-2 production was consid-
ered final at this stage.
Conclusion/discussion
In the past, production of rSAK or its several molecular
variants has been carried out in a number of expression
systems, including E. coli, B. subtilis and P.pastoris.
Table 5 (below) gives an overview of published data.
In addition, in this study, we have shown the methylo-
trophic yeast H. polymorpha is highly suitable for the ex-
pression of a sequence-optimized rSAK variant, rSAK-2,
of reduced immunogenic potential.
Initial kinetic fermentation and medium composition
data obtained from high throughput microreactors at a 1
mL scale provided a very reliable and robust basis for
successfully scaling the laboratory process for rSAK-2Table 5 Overview of different Staphylokinase expression syst
No Expression system SAK Productivity [mg/Lbroth] Cultivation
1 E. coli > 50 (not def
2 E. coli > 175 Fermen
3a B. subtilis 140 Shake f
3b B. subtilis 337 Fermen
4a P.pastoris 110 Fermen
4b E. coli 300-400 Shake f
5 E. coli 2800 Fermen
6 P.pastoris ~ 1000 Shake flask (w/o
7 P.pastoris Shake flask (w -
8 H. polymorpha ~ 1100 Fermenproduction to large scale fermenters (stirred tank bior-
eactors). During upstream process development and up-
scaling of fermentations over almost 5 orders of magni-
tude, we were able to systematically optimize the fer-
mentation process in a stepwise manner to attain high
levels of rSAK-2 expression and secretion. Further
optimization of the process included the use of an in-
house developed medium containing both undefined
supplements (peptone and yeast extract) and defined
components (components of SYN6 medium). We
showed the use of this medium resulted in significantly
higher yields of rSAK2 compared to “classical” unmodi-
fied SYN6 growth medium, which has often been used
for H. polymorpha fermentations [11].
Thus, a simple, relatively fast, robust and reproducible
fermentation protocol was developed that, on implemen-
tation at the large scale, yielded concentrations greater
than 1g/L of the intact, biologically active, rSAK-2 pro-
tein. In essence, this fermentation protocol consists of
only two phases: a glycerol batch phase and a methanol/
glycerol fed-batch phase. It therefore eliminates the need
for a glycerol de-repression fed-batch phase before the
methanol/glycerol induction fed-batch phase, as is usualems published to date
system Volume [L] SAK - glycosylation [Yes/No] Reference
ined) 2.7 No [8]
ter 10-15 No [19]
lask 0.25 No [20]
ter 2 No [20]
ter < 5 Partially yes [13]
lask 0.1 No [13]
ter 2 No [21]
-tunicamycin) 0.05 Yes [17]
tunicamycin) 0.05 No [17]
ter 80 No -
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tation time was considerably shortened, though relatively
high cell densities and very high rSAK-2 protein expres-
sion levels were still maintained.
Compared to other expression systems, as listed in
Table 5, H. polymorpha has several key advantages:
1. With a simple fermentation protocol, the secreted
protein, rSAK-2, accumulates in high concentration
in the cell culture supernatant. When compared to
unwieldy extraction from inclusion bodies, typical for
E. coli, secretion leads to simplification of subsequent
downstream processing, and thus has a positive
impact on the overall process’ economics.
2. The intended product, rSAK-2, is secreted as a
biologically active, non-glycosylated protein.
Compared with expression in P. pastoris, our process
does not require addition of tunicamycin for the
suppression of glycosylation [17].
3. Compared with expression in B. subtilis or E. coli,
where micro-heterogeneity – in particular, N-
terminal truncated SAK-variants lacking 6 – 11 N-
terminal amino acids – is of major concern [8,20],
rSAK-2 is secreted in a highly homogeneous and
relatively pure form (Figure 6), thus simplifying its
final purification.
4. Compared with other expression systems, expression
in H. polymorpha lends itself to the implementation
of a relatively simple final process design that permits
an easy scale-up and incorporates a high degree of
process’ robustness.
Altogether, our optimized process resulting in high
concentrations of target protein, namely rSAK-2, pro-
vides an excellent platform to initialize the downstream
process development of this promising fibrinolyic agent
for future clinical evaluation. We conclude our opti-
mized H. polymorpha-based upstream process approach
offers a significantly superior rSAK production strategy
than in other expression systems that are currently being
trialed. Our production strategy and findings should en-
courage the further development and pre-clinical evalu-
ation of rSAK-2 (or other rSAK variants) as a potential
replacement or alternative therapeutic fibrinolytic agent
for those therapeutics, e.g., SK and rt-PA, already in the
field.Methods
Gene constructs and expression plasmids
THR174 (called in this paper rSAK-1) has one possible
N-glycosylation recognition motif, comprised by amino
acids in positions 28 to 30 (Asn-Val-Thr), with Asn-28
representing the actual carbohydrate attachment site.Since glycosylated variants of SAK are known to be of
diminished activity [17,18,22] and H. polymorpha is
known to be able to perform N-glycosylation, amino
acid Thr-30 was substituted by an alanine for expression
of SAK in this yeast, resulting in a variant called rSAK-2,
which lacks the motif for glycosylation (see Figure 1).
The rSAK-1 and rSAK-2 genes were assembled by de
novo synthesis (GeneArt AG), streamlined for transcrip-
tion and adapted to H. polymorpha codon usage. Gene
synthesis also included the addition of flanking restric-
tion sites required for convenient subcloning into the
expression vector pFPMTMFα+. This vector bears the S.
cerevisiae URA3 selectable marker and also contains a
sequence encoding the S. cerevisiae preproMFα1 secre-
tion leader element between the FMD promoter and the
MOX terminator elements. Cloning into a unique Hin-
dIII site engineered into the leader sequence created an
in-frame fusion of the leader to the target gene
sequence.Generation of H. polymorpha strains secreting rSAK
The expression plasmids were transformed into the
uracil-auxotrophic H. polymorpha strain RB11 by elec-
troporation. Ura+ transformants were selected on YNB/
glucose plates (0.17% YNB w/o amino acids and 0.5%
ammonium sulfate/2% glucose containing 2% Bacto
agar) [23,24]. Single transformant colonies were cultured
in 3 mL cultivation tubes (shake flasks) in sequential
cycles of growth in liquid medium (40 hours at 180 rpm
at 37°C), first in selective medium (YNB/glucose) to in-
duce plasmid multiplication associated with spontaneous
genomic integration, and then in non-selective medium
(YPD; 2% Bacto peptone/1% yeast extract/2% glucose) to
eliminate any remaining unintegrated plasmids. This
'passaging' procedure has been proven to yield mitoti-
cally stable integrants containing multiple copies of the
transformed plasmid [24].
The integrant cell lines were screened for rSAK ex-
pression after cultivation in YPG medium (2% Bacto
peptone/1% yeast extract/1% glycerol). The presence of
glycerol as the sole carbon source resulted in de-
repression of the FMD promoter. After 40 hours of
growth at 180 rpm at 37°C, the cell-free culture superna-
tants were analyzed for the presence of rSAK protein by
immunoblotting with a mouse monoclonal antibody
developed against rSAK-1 (provided by ThromboGenics
NV). High-level secreting integrant lines were selected
and individualized by plating for single colonies. Ten ran-
domly selected colonies, each representing a genetically
pure clone, from each integrant line were re-screened as
described above to identify the most efficiently secreting
strains (data not shown). Strain rSAK-2 #1/4 was chosen
for further analyses described in this study.
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Microscale BioLectorW
Initial growth medium optimization and pH screening
were performed with the BioLectorW (m2p-labs GmbH,
Aachen, Germany), a system that allows for intensive
studies of 48 parallel fermentation processes at 1 mL
scale in microtiter plates. For these experiments, a spe-
cially shaped FlowerplateW was used that simultaneously
provides elevated oxygen transfer rates (OTR) and high
information content. Biomass concentration, fluores-
cence, pH and dissolved oxygen (DO) can be measured
for each individual well by non-invasive optical
measurements.
For growth medium optimization, the SYN6 medium
[11] was chosen as the ‘basic formulation’ and then
modified in several ways. Fermentations at different pHs
in the range from 4–8, operated in 0.5 steps, were first
performed. Based on the outcome of this evaluation, a
panel of 20 different plant peptones (Sigma, Art.-No.
11577) was used at 10 g/L for screening of positive
effects on rSAK-2 expression. Lastly, two different ex-
pression strategies were investigated in the BioLectorW,
namely a pulsed glycerol-peptone fed-batch and a
methanol-induced culture. Glycerol, peptone, as well as
methanol, were each dosed at 10 g/L (final concentra-
tion). A 100 mM phosphate buffer was used to maintain
the pH value at 6.5.
All small scale experiments were inoculated with over-
night grown YPD shake flask cultures at an initial OD600
of 1.0. Cultivation in the BioLectorW was carried out at
30°C and shake frequencies of 1000–1300 rpm (3 mm
diameter), thus eliminating oxygen deprivation. Process
parameters were measured in a cycle of 10 minutes.
Small scale shake flasks
Batch shake flask studies were performed firstly by con-
ducting fermentations at the temperatures 30°C or 37°C.
Further media optimization trials in the shake flask scale
followed the temperature comparison. An overnight
grown YPG culture was used to inoculate shake flask
cultivations in 500 mL baffled flasks with a working vol-
ume of 100 mL: different in-house developed medium
variants based on SYN6 medium were tested. All media
were supplemented with 2% w/v glycerol as carbon
source. Cultures were shaken in an incubator at 30°C
and 180 rpm for 72 hours. Samples were taken every
24 hours for OD600 and pH measurements. The rSAK-
2 concentration was analyzed using RP-HPLC.
Final growth medium optimization and fine-tuning
was performed in fed-batch mode. Following of above
mentioned cultivation procedures, a feeding solution
(FS) containing peptone and yeast extract as well as
methanol and glycerol was added to the cultures batch-
wise at a rate of 10 mL feed per 100 mL culture every 24hours starting at 24 hours of fermentation. Flasks were
shaken at 30°C and 180 rpm for a total of 96 hours.
Samples were taken every 24 hours for OD600 and pH
measurement. The rSAK-2 concentration was deter-
mined using RP-HPLC analysis.
Stirred bioreactors of 300 mL, 2 L, 8 L and 80 L scale
400 mL DASGIP parallel stirred tank bioreactors (DAS-
GIP AG) with a maximum working volume of 300 mL
were used for fed-batch process optimization, while a 3 L
Biostat B-Plus, a 15 L Biostat C and a 150 L Biostat D
(Sartorius Stedim Biotech) system with a maximum work-
ing volume of 2 L, 10 L and 100 L, respectively, were used
for scale-up studies and protocol consistency trials. For all
bioreactor studies, cells were grown in an in-house devel-
oped medium supplemented with 2% (w/v) glycerol as a
carbon source. After sterilization, the medium was inocu-
lated with an appropriate volume of an overnight grown
shake flask YPG culture to reach an initial OD600 of 1.5 –
2.0. The pH was measured with a standard Ingold probe
and controlled using either 42.5% (w/v) phosphoric acid
solution or 17.3% (v/v) ammonium hydroxide solution.
Foam formation was controlled manually using a 10%
(w/w) Struktol solution.
The fermentation process was divided into a glycerol
batch phase (19–22 hours) and methanol/glycerol fed-
batch phase (24–25 or 49–51 hours). The period of fer-
mentation was set to 70–73 hours. During the batch
phase, cells continuously consume glycerol present in
the growth medium. Depletion of the carbon source is
signaled by a sharp increase in dissolved oxygen (DO)
concentration. At the carbon source depletion signal, the
medium was supplemented with a mixture of methanol/
glycerol/peptone/yeast extract to induce expression of
the heterologous protein. For the trials on a 300 ml
scale, the air flow rate was 0.5 L/min with 500 rpm stir-
ring speed. Due to the larger volume and the different
geometry of the 2 L vessel, the air flow rate herein had to
be adjusted to 2 L/min and the stirring speed to 800 rpm.
Temperature was kept constant throughout the fermen-
tation at 30°C.
Up to 3 samples were drawn from the fermenter at
defined times daily for OD600 measurement. The rSAK-2
concentration was measured by RP-HPLC. In addition,
final samples were subjected to further protein analysis
using Western Blot. At the end of the fermentation, cells
were pelleted by centrifugation at 4500 rpm for 10 min-
utes at 4°C. The cell pellet was discarded and the super-
natant was subjected to sterile filtration and stored at
−20°C for further downstream processing. Alternatively,
at the 8 L and 80 L culture volumes, tangential flow fil-
tration using a Sartocon Hydrosart (Sartorius Stedim
Biotech) membrane with a 0.45μm cut-off was applied
for cell-free supernatant harvest.
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Optical density
Optical density (OD) measurement at an absorbance
reading between 0.1 and 0.5 at 600nm wavelength was
performed using an Ultrospec 6300 pro Visible/UV spec-
trophotometer (Amersham Biosciences).
Microscopic examination
Cells were examined for morphology and contamination
using an oil immersion MEIJI light microscope with a
total magnification of 1000-fold.
Protein analysis by RP-HPLC
All rSAK concentrations reported were measured by RP-
HPLC using a LC – 2010C HTapparatus from Shimadzu.
The culture broth was centrifuged for 10 minutes at
13200 rpm in a 5415R Centrifuge (Eppendorf AG) at
4°C to remove cells and cell debris. The clarified
supernatant was then filtered using 0.22μm syringe
driven filters (Millipore) before being subjected to an
RP-HPLC method that uses an PLRP-S (5μm) column
with gradient elution by 0.1% TFA in water and 0.1%
TFA in acetonitrile as mobile phase. Non-glycosylated
rSAK from E. coli (THR-174) served as reference and
calibration material.
Protein analysis by Western blot
Expression clone selection: Samples were prepared
by transferring 40 μL supernatant or cell-extract to
4x SAB buffer (reducing conditions) followed by heating
for 5 min at 95°C in a thermoblock. Afterwards, samples
of cell-extracts were centrifuged for 2 min at 13.000 rpm
to remove cell debris. Samples were stored at −20°C.
Loading volume was 7–21 μL per slot. SDS gel elec-
trophoresis was executed with precast gels in a
Criterion-Cell (BioRad). Voltage was adjusted to 150 V.
The following precast gels were used for the expression
studies: 4–20% Criterion precast gradient gel (BioRad
#354-0032) in a Criterion-Cell (BioRad). Electroblotting
was done using the BioRad Criterion blotter.
Fermentation screening: Supernatant samples were pre-
pared in the same way as for RP-HPLC. Gel electrophor-
esis was performed using NuPAGEW NovexW Mini 12%
Gels (Invitrogen) run at 200 volts for 40 minutes to separ-
ate proteins according to their molecular weight under
non reduced conditions. Proteins from gels were electro-
phoretically transferred at 25 volts for 1 hour onto 0.2 μm
nitrocellulose membrane. Immunodetection of rSAK was
performed using a mouse monoclonal antibody developed
against rSAK-1 (provided by ThromboGenics NV).
Plasminogen activation assay (PAA):
The activity of fermentation supernatant samples was
compared with SAK reference standard (STAR: NIBSCcatalogue number 94/718) as described in Collen et al.
[25] with minor differences:
The assay is based on the activation of plasminogen to
plasmin by SAK action. The resulting plasmin splits off
enzymatically from a chromogenic tripeptide derivative
p-nitroaniline. The kinetic course of this pigment release
is observed photometrically at 405 nm using a UV spec-
trophotometer equipped with a heat-controlled cell
holder. The measurement used is the rate of change of the
optical density for each sample (in terms of slope Absorb-
ance/second; A/sec). With each test series a standard
curve is recorded (plot of concentration on x-axis and
A/sec on y-axis) using SAK STAR 94/718. On the basis
of this standard curve, the activity of the samples is
established by reference to the curve by extrapolation of
obtained A/sec for each sample to obtain its concentra-
tion. The reaction is performed by mixing of 5μL of SAK
containing material with 78.5 μL 0.05 M sodium phos-
phate pH 7.4, 15 μL 10 μM human glu-Plasminogen
(HTI) and 1.5 μL 1 μM human Plasmin (HTI), this mix-
ture is incubated at 37°C for 5 minutes. 40 μl of the mix-
ture is added to cuvette containing 960 μL of prewarmed
3mM substrate (S-2403, Chromogenix) inside the heat-
controlled holder and measurement is directly started.
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